The new world of biosimilars: What diabetologists need to know about biosimilar insulins

British Journal of Diabetes and Vascular Disease

Volumn 10, Issue 4, 2010, Pages 163-171

  Krämer, Irene ^a   Sauer, Thomas ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Biosimilars; EMA; Manufacturing processes; Recombinant human insulin

Indexed keywords

C PEPTIDE; GROWTH HORMONE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; MONOCOMPONENT INSULIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SOMATOMEDIN C RECEPTOR;

AMINO ACID SEQUENCE; CHEMICAL MODIFICATION; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; DRUG TOLERABILITY; GLYCOSYLATION; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOGENICITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; MICROINJECTOR; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; PROTEIN QUALITY; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; QUALITY CONTROL; RELIABILITY; REVIEW;

EID: 77957122152     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651410369234     Document Type: Review

References (37)

1. European Medicines Agency. Press release: Marvel Life Sciences Ltd withdraws its marketing authorisation applications for Insulin Human rapid Marvel Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel. 16 January 2008. EMEA/2435/2008. London: EMA 2008
2. Schellekens H. Follow-on biologics: challenges of the 'next genera-tion'. Nephrol Dial Transplant 2005;20(suppl 4):iv31-6
3. European Medicines Agency. Questions and Answers on biosimilar medicines (similar biological medicinal products). 22 October 2008 Doc. ref. EMEA/74562/2006 rev.1. London: EMA, 2008. http://www. emea.europa.eu/pdfs/human/ pcwp/7456206en.pdf
4. Schellekens H, Ryff JC. 'Biogenerics': the off-patent biotech products Trends Pharmacol Sci 2002;23:119-21
5. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006;21(suppl 5):v13-16.
6. Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia 'epidemic' mystery completely revealed? Perit Dial Int 2007;27(suppl 2):S303-07
7. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antieryth-ropoietin antibodies in patients treated with recombinant erythropoi-etin. N Engl J Med 2002;346:469-75
8. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 2005;18:473-80
9. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21(suppl 5):v4-8
10. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology 2006;11:341-6
11. Mellstedt H, Niederwieser D. Ludwig H. The challenge of biosimilars Ann Oncol 2008;19:411-9
12. Grammer L. Insulin allergy. Clin Rev Allergy 1986;4:189-200
13. Fineberg SE, Kaabata TT, Finco-Kent D et al. Immunological responses to exogenous insulin. Endocrine Reviews 2007;28:625-52
14. Joshi SR, Parikh RM, Das AK. Insulin: history, biochemistry, physiology and pharmacology. J Assoc Physicians India 2007;55(suppl):19-25
15. Sattley M. The history of diabetes. Diabetes Health 2008. http://www. diabeteshealth.com/read/2008/12/17/71 5/the-history-of-diabetes/ (accessed 10 May 2009)
16. Teuscher A. The history of insulin. In: Insulin: A Voice for Choice. Basel Karger, 2007;10-13. http://content.karger.com/ProdukteDB/Katalogteile/ isbn3-8055/-83/-53/Insulin-02.pdf (accessed 10 May 2009)
17. Neubauer RP, Lin HY, Mathiszik B. Metabolic load of recombinant pro-tein production: inhibition of cellular capacities for glucose uptake and respiration after induction of a heterologous gene in Escherichia coli. Biotechnol Bioeng 2003; 83: 53-64.
18. Panda AK. Bioprocessing of therapeutic proteins from the inclusion bodies of Escherichia coli. Adv Biochem Eng Biotechnol 2003;85 43-93
19. Winter J, Lilie H, Rudolph R. renaturation of human proinsulin: a study on refolding and conversion to insulin. Anal Biochem 2002; 310:148-55
20. Singh AM, Panda AK. Solubilization and refolding of bacterial inclusion body proteins. J Bioscience Bioeng 2005;99:303-10
21. Committee for Medicinal Products for Human Use. Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant human insulin London: EMA, 2006. http://www.emea.europa.eu/pdfs/human/ biosimilar/3277505en.pdf (accessed 13 April 2009)
22. Beals JM, DeFilippis MR, Kovach PM. Insulin. In: Crommelin DJA, Sindelar RD, Meibohm B (eds.). Pharmaceutical Biotechnology Fundamentals and Applications, 3rd edition. Informa Healthcare New York, 2008;265-80
23. European Medicines Agency. Guideline on the suitability of the gradu-ation of delivery devices for liquid dosage forms. Doc ref EMEA/CHMP/ QWP/178621/2004. London: EMA, 2004. http://www.emea.europa eu/pdfs/human/qwp/ 17862104en.pdf (accessed 10 May 2009)
24. International Organization for Standardization. Peninjectors for medi-cal use. Part 1: Peninjectors. requirements and test methods (ISO 11608-1:2000). Geneva: ISO, 2000
25. Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insu-lin analogs and insulin pens. Diabetes Technol Ther 2008;10:247-56
26. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005; 27(suppl B):S89-100
27. Korytkowski M, Bell D, Jacobsen C, Suwannasari R. FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003; 25:2836-48
28. Wiecek A, Mikhail A. European regulatory guidelines for biosimilars Nephrol Dial Transplant 2006;21(suppl 5):v17-20
29. Committee for Medicinal Products for Human Use. Guideline on simi-lar biological medicinal products. London: EMA, 2005. http://www. emea.europa.eu/pdfs/human/biosimilar/043704en.pdf (accessed 13 April 2009)
30. Committee for Medicinal Products for Human Use. Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London: EMA, 2006 http:// www.emea.europa.eu/ pdfs/human/biosimilar/4934805en.pdf (accessed 13 April 2009)
31. Committee for Medicinal Products for Human Use. Guideline on simi-lar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London EMA, 2006 http://www.emea.europa.eu/pdfs/human/biosimilar/ 4283205en.pdf (accessed 13 April 2009)
32. European Medicines Agency. Pre-authorisation Evaluation of Medicines for Human Use. Withdrawal Assessment report for Insulin Human rapid Marvel. 21 February 2008. Document reference EMEA/CHMP/317778/2007 London: EMA, 2008. http://www.emea.europa.eu/humandocs/PDFs/EPAr/insulinhumanrapidmarvel/ 31777807en.pdf (accessed 1 May 2009)
33. European Medicines Agency. Preauthorisation Evaluation of Medicines for Human Use. Withdrawal Assessment report for Insulin Human Long Marvel. 21 February 2008. Document reference EMEA/CHMP/70349/2008 London: EMA: 2008. http://www.emea.europa.eu/humandocs/PDFs/ EPAr/insulinhumanrapidmarvel/ 7034908en.pdf (accessed 1 May 2009)
34. European Medicines Agency. Preauthorisation Evaluation of Medicines for Human Use. Withdrawal Assessment report for Insulin Human 30/70 Mixed Marvel. 21 February 2008. Document reference EMEA/ CHMP/70179/2008. London: EMA: 2008. http://www.emea.europa eu/humandocs/PDFs/EPAr/insulinhumanrapidmarvel/701790en. pdf (accessed 1 May 2009)
35. Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and nsulins. Br J Diabetes Vasc Dis 2010;10;90-7
36. Krämer I, Tredree R, Vulto AG. Points to consider in the evaluation of biopharmaceuticals. EJHP Practice 2008;14:73-6
37. Crommelin D, Bermejo T, Bissig M et al. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular-weight pharmaceuticals. Eur J Hosp Pharm Sci 2005;11:11-7